QVAR 100 MCG — DIN 02242030
BECLOMETHASONE DIPROPIONATE : 100 MCG · BAUSCH HEALTH, CANADA INC. · METERED-DOSE AEROSOL · wholesale supply in Canada
Health Canada status: MARKETED
What is QVAR?
QVAR 100 MCG contains BECLOMETHASONE DIPROPIONATE : 100 MCG. It is listed in the Health Canada Drug Product Database under DIN 02242030, held by BAUSCH HEALTH, CANADA INC., supplied as METERED-DOSE AEROSOL for INHALATION administration. Health Canada currently lists it as marketed, status dated 01-Jan-2021. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is QVAR used for?
QVAR (beclomethasone dipropionate) is indicated for the prophylactic management of steroid-responsive bronchial asthma in patients 5 years and older. QVAR may be effective in the management of asthmatics dependent or maintained on systemic corticosteroids and may permit replacement or significant reduction in the dosage of systemic corticosteroids.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How much does Beclometasone cost around the world?
Beclometasone is listed on 6 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Australia publishes a ex-manufacturer; Greece publishes a producer price (ex-factory); Italy publishes a prezzo al pubblico (classe A). Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed | Range |
|---|---|---|---|---|
| Australia | ex-manufacturer | 9 | 22 | AUD███.██ |
| Morocco | PPV (public price) | 9 | 15 | MAD███.██ |
| Italy | prezzo al pubblico (classe A) | 13 | 13 | EUR███.██ |
| Greece | producer price (ex-factory) | 9 | 9 | EUR███.██ |
| United Kingdom | hospital | 1 | 1 | GBP███.██ |
| South Africa | single exit price | 1 | 1 | ZAR███.██ |
61 pack listings across 42 brand entries and 6 price bases, refreshed 08 Sep 2026. Ranges span every Beclometasone pack in that market, so a high figure is usually a larger pack rather than the same product.
Canada publishes no comparable public list price. For a delivered Canadian price on a licensed account, verify your licence — it takes about a minute.
Is there a generic Beclometasone in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
6 holders have a Canadian DIN containing Beclometasone, across 17 DINs, of which 2 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| BAUSCH HEALTH, CANADA INC. | 2 | 2 | QVAR | Sourceable in Canada |
| GLAXO CANADA INC | 6 | 0 | BECLODISK PWR 100MCG/BLISTER, BECLODISK PWR 200MCG/BLISTER, BECLOFORTE 250MCG/AEM, BECLOVENT AEM 50MCG/AEM, BECLOVENT ROTACAPS 100MCG, +1 more | No marketed DIN |
| GLAXO WELLCOME INC. | 6 | 0 | BECLODISK - PWR INH 100MCG/BLISTER, BECLODISK - PWR INH 200MCG/BLISTER, BECLOFORTE INHALER - AEM INH 250MCG/AEM, BECLOVENT - AEM 50MCG/AEM, BECLOVENT ROTACAPS - INH 100MCG/CAPSULE, +1 more | No marketed DIN |
| ALTIMED PHARMA INC. | 1 | 0 | ALTI-BECLOMETHASONE DIPROPIONATE INHALER 50MCG/MD | No marketed DIN |
| PHARMACO CANADA INC. | 1 | 0 | BECLOMETHASONE DIPROPIONATE ORAL INHALER | No marketed DIN |
| SCHERING-PLOUGH CANADA INC | 1 | 0 | VANCERIL AEM 50MCG | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 100 MCG |
|---|---|
| Dosage form | METERED-DOSE AEROSOL |
| Route | INHALATION |
| Pack configuration (monograph) | null |
| Storage | null |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
Substance and classification
| Active substance | Beclometasone |
|---|---|
| ATC code | R03BA01 |
| AHFS class | 68:04.00 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02242030 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2242030 |
| Brand name | QVAR |
| Generic / active ingredient | BECLOMETHASONE DIPROPIONATE : 100 MCG |
| Market authorization holder | BAUSCH HEALTH, CANADA INC. |
| Health Canada schedule | Prescription |
| ATC code | R03BA01 |
| ATC anatomical main group | R — Respiratory system |
| ATC therapeutic subgroup | R03BA |
| Current status | MARKETED |
| Status date | 01-Jan-2021 |
| Original market date | 2000-05-29 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
How is it administered?
Administer by oral inhalation only. Adults (12+): 100-800 mcg/day in divided doses. Pediatrics (5-11): 50-100 mcg twice daily. Titrate to the lowest effective dose. Rinse mouth after use.
Included because it drives pack selection and wastage. Consult the monograph.
Contraindications
Primary treatment of status asthmaticus or acute asthma; moderate to severe bronchiectasis; untreated fungal, bacterial, or tuberculous respiratory infections; hypersensitivity to ingredients.
Warnings and precautions
Risk of adrenal insufficiency when transferring from systemic steroids. Paradoxical bronchospasm may occur. Not for acute attacks. Potential for HPA axis suppression and reduced bone density.
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
2 of 17 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| QVAR | 50 MCG | METERED-DOSE AEROSOL | BAUSCH HEALTH, CANADA INC. | MARKETED | 02242029 |
| ALTI-BECLOMETHASONE DIPROPIONATE INHALER 50MCG/MD | 50 MCG | METERED-DOSE AEROSOL | ALTIMED PHARMA INC. | CANCELLED POST MARKET | 00872334 |
| BECLODISK - PWR INH 100MCG/BLISTER | 100 MCG | POWDER | GLAXO WELLCOME INC. | CANCELLED POST MARKET | 02213710 |
| BECLODISK - PWR INH 200MCG/BLISTER | 200 MCG | POWDER | GLAXO WELLCOME INC. | CANCELLED POST MARKET | 02213729 |
| BECLODISK PWR 100MCG/BLISTER | 100 MCG | POWDER | GLAXO CANADA INC | CANCELLED POST MARKET | 00828521 |
| BECLODISK PWR 200MCG/BLISTER | 200 MCG | POWDER | GLAXO CANADA INC | CANCELLED POST MARKET | 00828548 |
| BECLOFORTE 250MCG/AEM | 250 MCG | METERED-DOSE AEROSOL | GLAXO CANADA INC | CANCELLED POST MARKET | 00897353 |
| BECLOFORTE INHALER - AEM INH 250MCG/AEM | 250 MCG | METERED-DOSE AEROSOL | GLAXO WELLCOME INC. | CANCELLED POST MARKET | 02215055 |
| BECLOMETHASONE DIPROPIONATE ORAL INHALER | 50 MCG | METERED-DOSE AEROSOL | PHARMACO CANADA INC. | CANCELLED POST MARKET | 02079976 |
| BECLOVENT - AEM 50MCG/AEM | 50 MCG | METERED-DOSE AEROSOL | GLAXO WELLCOME INC. | CANCELLED POST MARKET | 02216531 |
2 · Same class — other molecules in ATC R03BA
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Fluticasone | AERMONY RESPICLICK · APO-FLUTICASONE HFA · FLOVENT DISKUS · FLOVENT HFA · +10 more | 27 | 12 | Yes |
| Budesonide | PULMICORT NEBUAMP 0.125 MG/ML · PULMICORT NEBUAMP 0.25 MG/ML · PULMICORT NEBUAMP 0.5 MG/ML · PULMICORT TURBUHALER · +2 more | 12 | 12 | Yes |
| Mometasone | ASMANEX TWISTHALER | 3 | 3 | Yes |
| Beclometasone | ALTI-BECLOMETHASONE DIPROPIONATE INHALER 50MCG/MD · BECLODISK - PWR INH 100MCG/BLISTER · BECLODISK - PWR INH 200MCG/BLISTER · BECLODISK PWR 100MCG/BLISTER · +12 more | 17 | 2 | Yes |
| Ciclesonide | ALVESCO | 3 | 2 | Yes |
| Fluticasone Furoate | ARNUITY ELLIPTA | 2 | 2 | Yes |
| Flunisolide | BRONALIDE INHAL 250MCG/AEM | 1 | 0 | Not in Canada |
| Triamcinolone | AZMACORT | 1 | 0 | Not in Canada |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC R03B
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| R03BB | Aclidinium Bromide · Glycopyrronium Bromide · Ipratropium Bromide · Tiotropium Bromide · Umeclidinium Bromide | 37 | 15 |
| R03BC | Cromoglicic Acid · Nedocromil | 11 | 0 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is QVAR called?
The same molecule, Beclometasone, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| Trimbow | Latin | Australia |
| CORTIVENT | Latin | Morocco |
| Fostair | Latin | Australia |
| MIFLASONE | Latin | Morocco |
| AIRCORT | Latin | Morocco |
| BECLOJET | Latin | Morocco |
| BECONASE | Latin | Morocco |
| CLENIDERM | Latin | Morocco |
| CLENIL FORTE | Latin | Morocco |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.